Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This is a single centre, open-label, non-randomised study to assess the mass balance recovery, absorption, metabolism, and excretion of a single oral dose of [14C]-NT-814 in healthy male subjects. It is planned to enrol 6 subjects. Each subject will receive a single dose of 120 mg [14C] NT-814 containing not more than (NMT) 5.6 megabecquerel (MBq) [14C], administered as an oral suspension in the fasted state. Subjects will remain in the study until a mass balance cumulative recovery of >90% and <1% of the dose administered has been collected in urine and faeces within 2 separate, consecutive 24 hour periods.
Description: Cumulative amount of total radioactivity excreted in urine
Measure: Mass Balance Recovery of Total Radioactivity: CumAe (Urine) Time: Day 45 (maximum)Description: Cumulative amount of total radioactivity excreted in urine expressed as a percentage of the radioactive dose administered
Measure: Mass Balance Recovery of Total Radioactivity: Cum%Ae (Urine) Time: Day 45 (maximum)Description: Cumulative amount of total radioactivity excreted in faeces
Measure: Mass Balance Recovery of Total Radioactivity: CumAe (Faeces) Time: Day 45 (maximum)Description: Cumulative amount of total radioactivity excreted in faeces expressed as a percentage of the radioactive dose administered
Measure: Mass Balance Recovery of Total Radioactivity: Cum%Ae (Faeces) Time: Day 45 (maximum)Description: Cumulative amount of total radioactivity excreted in urine and faeces combined
Measure: Mass Balance Recovery of Total Radioactivity: CumAe(Total) Time: Day 45 (maximum)Description: Cumulative amount of total radioactivity excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered
Measure: Mass Balance Recovery of Total Radioactivity: Cum%Ae (Total) Time: Day 45 (maximum)Description: Area under the curve from time 0 to the time of last measurable concentration
Measure: AUC 0-last Time: 0 - 432 hoursDescription: Maximum observed concentration of NT-814
Measure: C max of NT-814 Time: 0 - 432 hoursDescription: Amount of total radioactivity excreted in urine
Measure: Ae(urine) Time: Day 45 (maximum)Description: Amount of TR excreted in urine expressed as a percentage of the radioactive dose administered
Measure: %Ae(urine) Time: Day 45 (maximum)Description: Amount of total radioactivity excreted in faeces
Measure: Ae(faeces) Time: Day 45 (maximum)Description: Amount of TR excreted in faeces expressed as a percentage of the radioactive dose administered
Measure: %Ae(faeces) Time: Day 45 (maximum)Description: Amount of total radioactivity excreted in urine and faeces combined
Measure: Ae(total) Time: Day 45 (maximum)Description: Amount of TR excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered
Measure: % Ae(total) Time: Day 45 (maximum)Description: Cumulative amount of TR excreted in urine
Measure: CumAe(urine) Time: Day 45 (maximum)Description: Cumulative amount of TR excreted in urine expressed as a percentage of the radioactive dose administered
Measure: %CumAe(urine) Time: Day 45 (maximum)Description: Cumulative amount of TR excreted in faeces
Measure: CumAe(faeces) Time: Day 45 (maximum)Description: Cumulative amount of TR excreted in faeces expressed as a percentage of the radioactive dose administered
Measure: %CumAe(faeces) Time: Day 45 (maximum)Description: Cumulative amount of TR excreted in urine and faeces combined
Measure: CumAe(total) Time: Day 45 (maximum)Description: Cumulative amount of TR excreted in urine and faeces combined expressed as a percentage of the radioactive dose administered
Measure: %CumAe(total) Time: Day 45 (maximum)Description: Evaluation of whole blood:plasma concentration ratios for TR
Measure: Evaluation of the extent of distribution of Total Radioactivity (TR) into blood cells Time: Up to 45 daysDescription: Chemical structure identity of relevant metabolites of NT-814 accounting for more than 5% of circulating Total Radioactivity
Measure: Chemical structure identity of relevant metabolites of NT-814 Time: Up to 45 daysDescription: Tabulation of all treatment emergent adverse events by body system
Measure: Adverse events Time: Up to 45 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports